espr – Scalper1

Esperion Drug Update Gets Mixed Wall Street Reaction

Small drug developer Esperion Therapeutics (ESPR) seesawed on the stock market in heavy early trading Tuesday as analysts gave a mixed reception to the company’s update late Monday on its cholesterol-drug candidate. Esperion said Monday that in its end-of-phase-two meeting with the FDA on its candidate ETC-1002 last week, the agency said it would not require cardiovascular outcomes data — data on whether the drug prevents heart attacks — in the

Esperion Up As UBS Touts Cholesterol Drug

Shares of development-stage pharmaceutical firm Esperion Therapeutics (ESPR) jumped 11% Wednesday after UBS initiated coverage of Esperion stock with a buy rating, praising its cholesterol drug candidate. Analyst Andrew Peters wrote that ETC-1002, a drug lowering LDL cholesterol that yielded positive phase 2b trial results last month, could present further upside even for a stock that’s already more than doubled this year. He says that the drug